XOSPATA (gilteritinib) Patient Assistance Program
Don’t let the high cost of brand specialty FLT3-targeted AML therapy disrupt your treatment. We help eligible patients access Xospata (gilteritinib) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Xospata (gilteritinib) is FDA-approved for adult patients with relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutations as detected by an FDA-approved test. It is a selective oral FLT3 inhibitor used as monotherapy (not in combination with chemotherapy).
- Without assistance, Xospata costs commonly run approximately $22,000–$27,000 per 30-day supply.
- Through AffordMyPrescriptions, qualifying patients can access Xospata for a flat $69.95 per month — our advocacy team manages the entire enrollment, refills, and renewal process.
- There is no generic Xospata in the U.S. as of 2026. Other FLT3 inhibitors include midostaurin (Rydapt — for newly diagnosed FLT3+ AML with chemotherapy) and quizartinib (Vanflyta — newer, for newly diagnosed FLT3-ITD+ AML with chemotherapy and as maintenance). For relapsed/refractory FLT3+ AML, Xospata is generally the preferred targeted therapy.
What Is Xospata Prescription Assistance Program?
The Xospata Prescription Assistance Program is a manufacturer-sponsored initiative that provides Xospata at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for FLT3+ relapsed/refractory AML patients who are uninsured or underinsured, as well as Medicare Part D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, oncology coordination, FLT3 mutation documentation, prior-authorization documentation, specialty pharmacy logistics, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment.
Pharmacy Price Comparison
- Without assistance, Xospata costs roughly $22,000–$27,000/month. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$26,000 | Save substantially |
| CVS Pharmacy | ~$27,000 | Save substantially |
| Walmart | ~$23,000 | Save substantially |
| Costco | ~$22,500 | Save substantially |
Specialty Pharmacy | ~$24,000 | Save substantially |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Xospata Prescription Program?
The Patient Assistance Program is free to apply for and provides Xospata at no medication cost if approved. Our $69.95/month service covers full advocacy.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Xospata:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $22,000–$27,000 per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Xospata assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Xospata Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Xospata:
Xospata (gilteritinib) is a once-daily oral selective FLT3 inhibitor used as monotherapy for relapsed or refractory FLT3-mutated AML in adults. It targets both FLT3-ITD and FLT3-TKD mutations, including some resistance mutations that arise during treatment with earlier FLT3 inhibitors.
How Xospata Works:
Gilteritinib is a highly selective FLT3 inhibitor that also possesses some AXL kinase activity to target the genetic mutations found in approximately 30% of AML patients. These activating mutations normally cause continuous kinase activity that drives the rapid proliferation of leukemic cells, resulting in a historically poor prognosis with chemotherapy alone. Compared to first-generation inhibitors like midostaurin, gilteritinib offers superior selectivity, fewer off-target effects, and efficacy against certain resistance mutations. Clinical data from the ADMIRAL trial demonstrated that it improves overall survival compared to salvage chemotherapy, establishing it as the preferred targeted monotherapy for relapsed or refractory FLT3-positive AML.
Form and use:
Marketed under the brand name Xospata, this medication is administered orally at a standard dose of 120 mg taken once daily, either with or without food. Treatment is meant to be continued continuously until the patient experiences disease progression or unacceptable toxicities. While on therapy, patients must undergo regular monitoring of their complete blood count (CBC), comprehensive metabolic panels, creatine kinase (CK) levels, and electrocardiograms (ECGs). For eligible patients, this targeted therapy often serves as a clinical bridge leading to an allogeneic stem cell transplant.
Generic availability:
As of 2026, there is no generic version of Xospata commercially available in the United States. Other existing FLT3 inhibitors include midostaurin and the newer drug quizartinib, both of which are utilized alongside chemotherapy for newly diagnosed FLT3-positive AML cases. For the relapsed or refractory setting, gilteritinib remains the preferred targeted monotherapy option. Alternative medical approaches for managing relapsed AML include utilizing various salvage chemotherapy regimens, venetoclax-based combination therapies, or proceeding to an allogeneic stem cell transplant as a definitive treatment.
Warnings:
Xospata carries serious Boxed Warnings for differentiation syndrome, a potentially life-threatening condition characterized by fever, dyspnea, hypoxia, and fluid accumulation that requires immediate corticosteroid treatment. It also features Boxed Warnings for posterior reversible encephalopathy syndrome (PRES), severe QTc prolongation, and pancreatitis. Additionally, patients must be monitored for other severe adverse events such as transaminitis, pneumonia, sepsis, dizziness, and embryo-fetal toxicity. Blood counts must also be watched closely due to risks of treatment-induced anemia, thrombocytopenia, and neutropenia.
FAQ (Frequently Asked Questions)
How Much Does Xospata Cost Without Insurance?
Xospata costs approximately $22,000–$27,000 per 30-day supply. Through AffordMyPrescriptions, qualifying patients receive Xospata at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
Why Do I Need FLT3 Mutation Testing?
Xospata is approved specifically for FLT3-mutated AML — both FLT3-ITD and FLT3-TKD mutations are responsive. FLT3 mutation testing on bone marrow is essential before starting. Without an FLT3 mutation, Xospata is not effective. About 30% of AML patients have FLT3 mutations. Mutation status should be reassessed at relapse (clonal evolution can change mutations).
How Is Xospata Different From Rydapt?
Both target FLT3. Rydapt (midostaurin) is a multi-kinase inhibitor used in newly diagnosed FLT3+ AML with intensive chemotherapy (induction + consolidation). Xospata (gilteritinib) is a more selective FLT3 inhibitor used as MONOTHERAPY in relapsed/refractory FLT3+ AML — including patients who progressed after midostaurin. These FLT3 inhibitors are used at different points in the AML treatment journey.
What Is Differentiation Syndrome?
When FLT3+ leukemic cells are induced to differentiate (mature) by gilteritinib, the differentiating cells can cause a systemic inflammatory response — fever, shortness of breath, fluid retention, low blood pressure, organ dysfunction. This ‘differentiation syndrome’ can be severe or fatal if not recognized and treated promptly. Treatment: high-dose corticosteroids (dexamethasone 10 mg IV q12h), supportive care, sometimes temporary discontinuation of gilteritinib. Tell your oncologist immediately about new shortness of breath, fluid retention, fever, or weight gain.
Should I Have A Stem Cell Transplant After Xospata?
If you respond to Xospata and are eligible (age, performance status, donor availability), allogeneic stem cell transplant offers the best chance of cure for FLT3+ relapsed/refractory AML. Many patients use Xospata as a bridge to transplant — achieving remission, then proceeding to transplant. Post-transplant, gilteritinib maintenance can be considered. Discuss transplant eligibility with your hematology/oncology team.
Can I Get Xospata Through The PAP If I Have Medicare?
Yes. Medicare Part D beneficiaries can typically qualify, especially if you face specialty-tier copays. The manufacturer’s commercial copay savings program is reserved for commercially insured patients only — but the underlying PAP supports Medicare patients who meet income criteria.
What If My Application Is Denied?
If denied, we explore alternatives — discussing salvage chemotherapy regimens, venetoclax-based combinations, stem cell transplant directly, clinical trials, the manufacturer’s copay program for commercially insured patients, or independent foundations such as the Leukemia & Lymphoma Society, PAN Foundation, or HealthWell Foundation. If we cannot find a path, you won’t be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Xospata, our team may be able to help you access assistance programs designed to make brand specialty FLT3-targeted AML therapy affordable. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.